Sino Biopharmaceutical (HK:1177) has released an update. Sino Biopharmaceutical has announced positive results from its Phase III study of ...

AstraZeneca and Daiichi Sankyo have withdrawn their marketing authorisation application in the European Union (EU) ...

Telisotuzumab vedotin is under clinical development by AbbVie and currently in Pre-Registration for Non-Small Cell Lung Cancer.

The latest announcement is out from AstraZeneca ( (AZN) ).

Woman from Central Texas thought she had allergies. Then she learned she had lung cancer, although she never smoked.

Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/Nasdaq: AZN) have voluntarily withdrawn the marketing authorization ...

A Chinese player entered the U.S. non-small-cell lung cancer (NSCLC) arena as the U.S. FDA cleared Xcovery Holdings Inc.’s Ensacove (ensartinib) as a first-line therapy for adults with anaplastic ...

2024 — Researchers have demonstrated that patients with metastatic non-squamous non-small cell lung cancer (NSCLC) harboring specific mutations in the STK11 ... Scientists Discover That Special ...

Cambridge: AstraZeneca's Tagrisso (osimertinib) has been approved in the European Union (EU) for the treatment of adult ...

A home-based exercise program boosted exercise capacity and quality of life among patients after lung cancer surgery but did not improve self-reported physical function, a new study found.

The FDA has approved Xcovery Holdings' ALK inhibitor Ensacove for first-line treatment of adults with anaplastic lymphoma ...

AstraZeneca ( (GB:AZN) ) has shared an update. AstraZeneca and Daiichi Sankyo have withdrawn their EU marketing application for datopotamab deruxtecan for advanced nonsquamous non-small cell lung ...